Glipizide: Clinical Trials

12 trials of Glipizide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed. 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 312Completed 12

Follow Glipizide: new trials by email Literature Review of Glipizide trials Research Report on Glipizide

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)
Omarigliptin, Placebo to omarigliptin, Glipizide - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC2132012-10-022018-08-09
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
Sitagliptin, Comparator: Placebo, Pioglitazone - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC3132009-04-152017-05-23
Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus
Alogliptin, Metformin, Glipizide - Type 2 Diabetes Mellitus
Phase 3CompletedTakeda26392009-03-012013-12-03
Efficacy and Safety of Alogliptin Compared to Glipizide in Elderly Diabetics
Alogliptin, Glipizide - Diabetes Mellitus
Phase 3CompletedTakeda4412008-06-012013-05-24
Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients
dapagliflozin, glipizide, metformin hydrochloride - Type 2 Diabetes
Phase 3CompletedAstraZeneca12172008-03-012015-03-30
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and End-Stage Renal Disease (MK-0431-073 AM1)
Sitagliptin, Glipizide - Diabetes Mellitus, Type 2, End-Stage Kidney Disease
Phase 3CompletedMerck Sharp & Dohme LLC1292007-10-192017-05-12
Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)
Sitagliptin, Glipizide, Placebo for Sitagliptin - Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Phase 3CompletedMerck Sharp & Dohme LLC4262007-10-092017-05-12
Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)
sitagliptin, Comparator: Placebo, rosiglitazone - Type 2 Diabetes Mellitus
Phase 3CompletedMerck Sharp & Dohme LLC2622006-06-122017-05-12
Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes
Glipizide, rosiglitazone maleate - Atherosclerosis
Phase 3CompletedGlaxoSmithKline6722005-01-012017-03-23
An Investigational Drug in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (0431-028)(COMPLETED)
sitagliptin, Placebo to Sitagliptin, glipizide - Diabetes Mellitus, Type 2, Chronic Renal Insufficiency
Phase 3CompletedMerck Sharp & Dohme LLC912004-10-012015-04-02
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024)
sitagliptin (MK0431), Comparator: glipizide - Diabetes Mellitus, Type 2
Phase 3CompletedMerck Sharp & Dohme LLC11722004-09-012016-08-26
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
Sitagliptin (MK0431), Placebo/Glipizide 5 mg, Metformin - Diabetes Mellitus, Type II
Phase 3CompletedMerck Sharp & Dohme LLC7012004-06-302017-05-05

Conditions studied

Diabetes Mellitus, Type 2 (11)  ·  Diabetes Mellitus (2)  ·  Renal Insufficiency, Chronic (2)  ·  Atherosclerosis (1)  ·  Dyslipidemias (1)  ·  Glucose Intolerance (1)  ·  Glucose Metabolism Disorders (1)  ·  Hyperglycemia (1)  ·  Hyperinsulinism (1)  ·  Kidney Failure, Chronic (1)  ·  Plaque, Atherosclerotic (1)

Sponsors

Merck Sharp & Dohme LLC (8)  ·  Takeda (2)  ·  AstraZeneca (1)  ·  GlaxoSmithKline (1)

Countries

Mexico (4)  ·  Argentina (3)  ·  Germany (3)  ·  India (3)  ·  Italy (3)  ·  Poland (3)  ·  Russia (3)  ·  South Africa (3)  ·  Spain (3)  ·  United States (3)  ·  Brazil (2)  ·  Canada (2)  ·  France (2)  ·  Hong Kong (2)  ·  Hungary (2)

Top investigators

Michael A. Nauck, Prof. Dr. med. (1)

Results publications

PMID 20194881, PMID 20456211, PMID 21477878, PMID 21816980, PMID 22742523, PMID 23116881, PMID 23248197, PMID 23352379, PMID 23529570, PMID 25633134, PMID 27787778, PMID 28449320

NIH funding

2008 (2)